NNC 55-0396 free base
NNC 55-0396 free base is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 free base selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 free base reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 free base inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
For research use only. We do not sell to patients.
- CAS No.: 357400-14-7
- Formula: C30H38FN3O2
- Molecular Weight:491.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Calcium Channel Isoforms
More
Biological Activity
|
CYP3A4 300 nM (IC50) |
CYP3A4 210 nM (Ki) |
CYP2D6 29 nM (IC50) |
CYP2D6 2.8 nM (Ki) |
T-type calcium channel |
NNC 55-0396 free base potently inhibits recombinant human CYP3A4 and CYP2D6 at 100 nM and 10 μM, with weaker or no inhibition of recombinant human CYP1A2, CYP2E1, CYP2C9, CYP2C19, and CYP2C8 at these concentrations[2].
NNC 55-0396 free base inhibits recombinant human CYP3A4 BFC debenzylation activity with an IC50 of 300 nM and a Ki of 210 nM[2].
NNC 55-0396 free base inhibits recombinant human CYP2D6 AMMC N-demethylation activity with an IC50 of 29 nM and a Ki of 2.8 nM[2].
NNC 55-0396 free base inhibits CYP3A4-mediated testosterone 6β-hydroxylase activity in human liver microsomes with an IC50 of 11.0 μM and a Ki of 3.9 μM[2].
NNC 55-0396 free base inhibits CYP2D6-mediated harmaline metabolism in human liver microsomes with an IC50 of 72.6 nM and a Ki of 57.1 nM[2].
NNC 55-0396 (1-20 μM; 72 h) free base inhibits the growth of HepG2 cells more potently in galactose medium than glucose medium[3].
NNC 55-0396 (1-5 μM; 5 h) free base dose-dependently inhibits hypoxia-induced HIF-1α protein stability in HepG2 cells, with a near-complete reduction at 5 μM after 4 h hypoxic incubation, without affecting HIF-1β levels[3].
NNC 55-0396 (1-5 μM; 5 h) free base dose-dependently increases the hydroxylation of HIF-1α in HepG2 cells under hypoxic conditions, with a 6-fold increase observed at 5 μM after 4 h incubation[3].
NNC 55-0396 (1-5 μM; 5 h) free base reduces hypoxia-induced mitochondrial ROS levels in HepG2 cells[3].
NNC 55-0396 (1 μM) free base decreases the half-life of hypoxia-stabilized HIF-1α in HepG2 cells, reducing it from over 80 minutes to less than 70 minutes[3].
NNC 55-0396 (1-5 μM; 5 h) free base inhibits Desferrioxamine-induced HIF-1α stabilization in HepG2 cells, with a 50% reduction observed at 5 μM after 4 h incubation[3].
NNC 55-0396 (1-5 μM; 75 min) free base reduces hypoxia-induced HIF-1α protein levels in HepG2 cells, with significant suppression observed at 1 μM and 5 μM[3].
NNC 55-0396 (1-5 μM; 75 min) free base inhibits hypoxia-induced phosphorylation of mTOR and p70S6K in HepG2 cells, with a 70% reduction in phospho-mTOR levels observed at 5 μM after 15 min hypoxic incubation[3].
NNC 55-0396 (1-5 μM; 17 h) free base dose-dependently reduces hypoxia-induced VEGF expression in HepG2 cells, with significant suppression observed at 1 μM and 5 μM after 16 h hypoxic incubation[3].
NNC 55-0396 (0.001-10 mM; 1 min) free base dose-dependently inhibits Kv currents in freshly isolated rabbit coronary arterial smooth muscle cells with an IC50 of 0.08 mM[4].
NNC 55-0396 free base potently blocks recombinant Cav3.1 T-type calcium channels in HEK293 cells with an IC50 of 6.8 μM, via a state-dependent[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human liver carcinoma HepG2 cells
-
Concentration:1 μM; 2 μM; 5 μM; 7 μM; 10 μM; 20 μM
-
Incubation Time:72 h
-
Result:Exhibited stronger inhibitory effects on cell growth in galactose medium than in glucose medium.
Increased glucose/galactose cell growth ratios significantly at concentrations of 5, 7, 10, and 20 μM.
-
Cell Line:human liver carcinoma HepG2 cells
-
Concentration:1 μM; 5 μM
-
Incubation Time:5 h
-
Result:Suppressed hypoxia-induced HIF-1α protein stability in a dose-dependent manner, with no effect on HIF-1β stability.
Reduced HIF-1α expression to ~80% of hypoxic control levels at 1 μM.
Reduced HIF-1α expression to ~20% of hypoxic control levels at 5 μM (p<0.001).\nIncreased the ratio of hydroxy-HIF-1α to total HIF-1α in a dose-dependent manner.
Increased the ratio to ~250% of control levels at 1 μM.
Increased the ratio to ~600% of control levels at 5 μM (p<0.001).
-
Cell Line:human liver carcinoma HepG2 cells
-
Concentration:1 μM; 5 μM
-
Incubation Time:5 h
-
Result:Inhibited DFO-induced HIF-1α stabilization.
Reduced HIF-1α expression to ~100% of DFO-treated control levels at 1 μM.
Reduced HIF-1α expression to ~50% of DFO-treated control levels at 5 μM (p<0.01).
-
Cell Line:human liver carcinoma HepG2 cells
-
Concentration:1 μM; 5 μM
-
Incubation Time:75 min
-
Result:Repressed hypoxia-induced phosphorylation of mTOR and p70S6K.
Reduced phospho-mTOR levels to 0.8-fold of hypoxic control levels at 1 μM.
Reduced phospho-mTOR levels to 0.3-fold of hypoxic control levels at 5 μM.
Reduced phospho-p70S6K levels to 0.9-fold and 0.8-fold of hypoxic control levels at 1 μM and 5 μM, respectively.
-
Cell Line:human liver carcinoma HepG2 cells
-
Concentration:1 μM; 5 μM
-
Incubation Time:17 h
-
Result:Decreased hypoxia-induced VEGF expression in a dose-dependent manner.
Reduced relative VEGF expression to ~220% of normoxic control levels at 1 μM (vs ~280% for hypoxic control; p<0.01).
Reduced relative VEGF expression to ~180% of normoxic control levels at 5 μM (p<0.01).
NNC 55-0396 (10-20 mg/kg; i.p.; every 2 days for 20 days) free base significantly reduces glioblastoma tumor weight by 40-60% and suppresses tumor angiogenesis via reduced HIF-1α, VEGF, and PECAM-1 expression in a subcutaneous mouse xenograft model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ddY mice (male, 3 weeks old, acclimated for a few weeks before experiments)[1]
-
Dosage:5 mg/kg; 20 mg/kg
-
Administration:i.p.; 2 doses
-
Result:Reduced MCAO/R-induced infarct area (at all measured distances from bregma) and infarct volume to ~30 mm3 (5 mg/kg i.p. pre-occlusion) and ~45 mm3 vs. vehicle ~70 mm3.
Tended to attenuate some neurological dysfunctions, including increased test latency in the passive avoidance test and reduced time spent in right-biased bending.
-
Animal Model:BALB/c-nu/nu (athymic nude) (4-week-old female, subcutaneous glioblastoma xenograft model)[3]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.; every 2 days for 20 days
-
Result:Reduced xenograft tumor volume and weight relative to vehicle controls.
Significantly reduced tumor weight (p<0.01 for 10 mg/kg, p<0.001 for 20 mg/kg).
Significantly reduced HIF-1α, VEGF, and PECAM-1 expression levels in tumor tissue.
Significantly decreased microvessel density (p<0.001 for 10 mg/kg, p<0.01 for 20 mg/kg).
Caused no weight loss or liver toxicity in treated mice.
Chemical Information
-
CAS No. 357400-14-7
-
Molecular Weight 491.64
-
Formula C30H38FN3O2
-
SMILES
O=C(C1CC1)O[C@]2([C@H](C3=CC=C(F)C=C3CC2)C(C)C)CCN(C)CCCC4=NC5=CC=CC=C5N4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Matsuda S, et al. NNC 55-0396, a T-type calcium channel blocker, protects against the brain injury induced by middle cerebral artery occlusion and reperfusion in mice. J Pharmacol Sci. 2019;140(2):193-196. [Content Brief]
[2]. Bui PH, et al. The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. Drug Metab Dispos. 2008;36(7):1291-1299. [Content Brief]
[3]. Kim KH, et al. NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction. J Mol Med (Berl). 2015;93(5):499-509. [Content Brief]
[4]. Son YK, et al. Ca2+ channel inhibitor NNC 55-0396 inhibits voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells. J Pharmacol Sci. 2014;125(3):312-319. [Content Brief]
[5]. Li M, et al. Towards selective antagonists of T-type calcium channels: design, characterization and potential applications of NNC 55-0396. Cardiovasc Drug Rev. 2005;23(2):173-196. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NNC 55-0396 free base Related Classifications
HY-50722B Related Classifications
Powered by Bioz